Autolus Therapeutics (NASDAQ:AUTL) Upgraded at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of Autolus Therapeutics (NASDAQ:AUTL) from a sell rating to a hold rating in a report issued on Thursday morning, Zacks.com reports.

According to Zacks, “Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies. The company’s pipeline of product candidate involved in development for the treatment of haematological malignancies and solid tumours. Autolus Therapeutics plc is based in London, United Kingdom. “

AUTL has been the subject of a number of other reports. HC Wainwright set a $18.00 price target on Sutro Biopharma and gave the stock a buy rating in a research note on Friday, May 17th. William Blair initiated coverage on shares of American Software in a report on Wednesday, April 3rd. They issued an outperform rating and a $12.03 target price on the stock. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $42.67.

NASDAQ:AUTL opened at $16.01 on Thursday. Autolus Therapeutics has a one year low of $14.80 and a one year high of $53.24. The stock has a 50-day moving average price of $17.18. The company has a debt-to-equity ratio of 0.12, a current ratio of 10.66 and a quick ratio of 10.66.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($0.69) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($0.11). The company had revenue of $1.96 million during the quarter, compared to analyst estimates of $0.30 million. On average, analysts predict that Autolus Therapeutics will post -3.07 EPS for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. lifted its holdings in Autolus Therapeutics by 4,011.3% in the fourth quarter. BlackRock Inc. now owns 202,973 shares of the company’s stock worth $6,666,000 after acquiring an additional 198,036 shares during the last quarter. CWM LLC bought a new position in Autolus Therapeutics in the first quarter worth about $1,105,000. Marshall Wace LLP lifted its holdings in Autolus Therapeutics by 93.4% in the first quarter. Marshall Wace LLP now owns 232,931 shares of the company’s stock worth $7,330,000 after acquiring an additional 112,489 shares during the last quarter. Geode Capital Management LLC bought a new position in Autolus Therapeutics in the fourth quarter worth about $322,000. Finally, Barclays PLC bought a new position in Autolus Therapeutics in the fourth quarter worth about $113,000. 43.37% of the stock is currently owned by hedge funds and other institutional investors.

About Autolus Therapeutics

Autolus Therapeutics plc, a biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1, a CD19-targeting programmed T cell therapy, which is in Phase I trial to reduce the risk of severe cytokine release syndrome; AUTO2, a dual-targeting programmed T cell therapy that is in Phase I/II clinical trial for the treatment of relapsed or refractory multiple myeloma; and AUTO3, a dual-targeting programmed T cell therapy, which is in Phase I/II clinical trials for treating relapsed or refractory diffuse large B-cell lymphoma.

Read More: What are the advantages to having securities held in street name?

Get a free copy of the Zacks research report on Autolus Therapeutics (AUTL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Autolus Therapeutics (NASDAQ:AUTL)

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply